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uremia) mechanism thereof remains obscure. Therefore, the aim of the study was to assess the effect of CDZ on in vitro 
activity of PMNL from healthy volunteers. PMNL (2~1O-~/ml) were incubated for lh with CDZ (high therapeutic 
concentration - 100 mg/l) and then intracellular calcium concentration ([Ca’+]i) changes, chemiluminescence and production 
of hydrogen peroxide upon fMLP stimulation (10m7M) were measured. To assess bactericidal capacity of PMNL tests for 
phagocytosis and intracellular killing of St. aureus were performed. 
In PMNL preincubated with CDZ enhanced phagocytosis (ie the number of St. aureus colonies cultured from lysed 
PMNL) was observed - (M-0.8x2106, QR-2.2x 106) versus control (M-0.52x106, QR-1.46~10~) (n=12, PcO.05). The 
intracellular killing (percentage of killed phagocytosed bacteria to all phagocytosed bacteria) was 32 x 15 versus 19 x 13% for 
cells preincubated with CDZ and controls, respectively (n=12, PcO.05). We observed no difference in intracellular calcium 
changes, chemiluminescence and hydrogen peroxide production upon fMLP stimulation. In conclusion - enhanced activity of 
preincubated with CDZ PMNL against St. aureus is not related to upregulation of classical activation pathway and 
production of toxic reactive oxygen species and requires further studies. 
4. Bronchial infection and systemic steroid therapy in a sample of patients with acute 
exacerbation of chronic bronchitis (AECB) 
l? BONFITTO, M. A. VALENZA*, G. CASTELLANA, F. GENTILE, I? LOMBARDI, G. RICCO, 
V. LAMORGESE, M. CORREALE” AND A. LIPPOLIS* 
Division of Pneumology, S. Michele M. Laureto Hospital, ASL Bal.5, Putignano (Ba), Italy 
*Laboratory of Bacteriology, I. R. C. C.S. “S.De Bellis”, Castellana Grotte (Ba), Italy 
We enrolled 96 consecutive patients (62 M and 34 F, aged 71 yrs), 65 hospitalized and 31 outpatients, evaluated at our 
Division of Pneumology for AECB. No patient had received any systemic antibiotic during the time period extending 30 days 
prior to enrohnent. We did not enrol patients with diagnosis of pneumonia, bronchiectasis, cystic fibrosis and other bronchial 
infection apart from chronic bronchitis, patients with previously diagnosed diseases of immune function and patients with 
neoplastic diseases. All the enrolled patients showed an increase of dyspnea, cough and sputum volume or a change in 
character of sputum. The patients had an obstructive respiratory pattern (FVC%pred 68.5; FEVl%pred 54.9; FEVl/FVC 
61.56%); thirty-nine patients had acute or chronic respiratory failure. 
We obtained 96 samples of sputum after cleaning the mouth with saline solution and we evaluated them with Gram stain to be 
sure that polymorphonuclear/epithelial cells ratio (Bartlett index) confirmed the provenience from the lower respiratory tract. In 
50 patients (52%) it was possible to perform an etiological diagnosis (more pathogen agents were isolated from 21 patients): B. 
catarrhalis (24%); C. albicans (24%); Enterobacter spp (2%); H. influenzae (40%); Klebsiella spp (4%); l? aeruginosa (10%); S. 
aureus (6%); Streptococcus spp (8%); S. pneumoniae (28%); other bacteria (10%). Thirty-four (68%) out of these 50 patients 
reported frequent use of systemic steroid therapy on the occasion of several episodes of AECB during the previous year. 
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In conclusion it can be said that the necessity of systemic steroid therapy should be strongly considered in relation to the 
obtainable advantages and to the possibility of the colonization of bronchial tree by infectious agents (only 35% out of the 
patients with negative sputum culture reported frequent use of systemic steroids). Further studies will investigate the possible 
relation between systemic steroid therapy and different bacterial species. 
5. The treatment of community acquired pneumonia with fluoroquinolones 
G. DOUGLAS CAMPBELL AND GLENN TILLOTSON* 
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The combination of a /3-lactam and a macrolide is currently widely recommended treatment for community-acquired 
pneumonia (CAP) which is effective against a wide spectrum of organisms. However, because of a dramatic increase in the 
incidence of pneumococcal strains that are resistant to penicillin and other antimicrobials and because physicians cannot 
readily differentiate pneumonia caused by typical or atypical pathogens, alternative therapies are needed. 
Several new fluoroquinolones have been developed with enhanced Gram-positive and Gram-negative activities as well as a 
broader spectrum, including atypical pathogens. In this study, in vitro results and clinical efficacy and safety of the 
fluoroquinolones have been compared with that of the currently accepted therapy for CAP, based on published information. 
In vitro, moxifloxacin and trovafloxacin were the most potent fluoroquinolones with MIC90 0.125 mg/L against S. pneumoniae. 
The clinical cure rate was highest with moxifloxacin, levofloxacin and clarithromycin, reaching cures 295% of patients at the 
end of treatment and maintaining these results at follow-up. The eradication rates confirmed the potency of moxifloxacin, 
which successfully eradicated Gram-positive and Gram-negative bacilli as well as atypical pathogens. The safety profiles of 
moxifloxacin and levofloxacin were good and comparable, while grepafloxacin had a significant incidence of taste perversion 
(26%) and nausea (13.8%) and sparfloxacin exhibited photosensitivity reactions (2.4%). 
Most of the newer fluoroquinolones have an improved efficacy and safety profile compared to the earlier drugs. Overall, 
moxifloxacin appears to be a promising alternative to existing therapy with the highest in vitro potency correlating well with 
excellent clinical efficacy and good safety. 
6. Duration of hospitalization of patients with pneumonia in relation to the existence 
of underlying diseases 
G. CHRYSOFAKIS, H. LAMBRAKIS, N. TZANAKIS, D. BOUROS, N. M. SIAFAKAS 
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The duration of hospitalization of patients with pneumonia may be different in patients with or without underlying diseases. 
The aim of this study was to investigate whether hospitalization time is different between patients with pneumonia who have 
or do not have underlying comorbidity. 
We studied 70 patients with pneumonia who were hospitalized during the years 1997-1998. Thirty of the patients (18 were 
male, smokers and 12 female non-smokers), mean (SD) age 35*10 years had no underlying disease. The other 40 patients 
(32 male smokers and 8 female non-smokers ), mean (SD) age 60*5 years, had underlying disease: COPD (n= 15),coronary 
artery disease (n= lo), diabetes mellitus (n= 12) and alcoholism (n=3) . 
In the first group, the average hospitalization time was 5?2 days, whereas in the second, 9?2 days (P=O.O27).This 
difference could not be attributed to differences in treatment. The mean age of the groups was significantly different 
(P=O.O12). 
Our results suggest that the existence of underlying diseases increases the hospitalization time of patients with community- 
acquired pneumonia. 
7. Pharrnacoeconomical analysis of AECB treatment using a computerised case report 
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In an outpatient setting we used a computerised case report form also to classify exacerbations of COPD (AECB) according 
to Anthonisen criteria (AcI, AcII, AcIII) and to calculate costs of different antibiotic treatments (ATR). Between 9/98 and 
